Vincent Amodru1, Carole Guerin2, Sarkis Delcourt3, Pauline Romanet4, Anderson Loundou5, Bruna Viana6, Thierry Brue1, Frédéric Castinetti1, Frédéric Sebag2, Karel Pacak6, David Taïeb7. 1. Department of Endocrinology, Conception University Hospital, Aix-Marseille University, Marseille, France. 2. Department of Endocrine Surgery, Conception University Hospital, Aix-Marseille University, Marseille, France. 3. Department of Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, 264, rue Saint-Pierre, 13385, Marseille, France. 4. Laboratory of Molecular Biology, Conception Hospital & CNRS, CRN2M UMR 7286, Aix-Marseille University, Marseille, France. 5. Department of Public Health, EA3279 Self-perceived Health Assessment Research Unit, La Timone University, Aix-Marseille University, Marseille, France. 6. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, Bethesda, MD, USA. 7. Department of Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, 264, rue Saint-Pierre, 13385, Marseille, France. david.taieb@ap-hm.fr.
Abstract
INTRODUCTION: 18F-FDOPA illustrates the properties of uptake and storage of catecholamines in pheochromocytomas (PHEOs). Until now, the relationship between 18F-FDOPA quantitative parameters and a PHEO secretory profile has not been specifically evaluated. MATERIALS AND METHODS: Fifty-six patients (56% females, median age: 47.5 yrs) with non-metastatic PHEO, evaluated by 18F-FDOPA PET/CT, were included in this retrospective study. Forty-five patients had negative genetic testing (80.4%); five patients (8.9%) had RET, two patients (3.6%) had SDHB, two had SDHD (3.6%), one patient (1.8%) had NF1, and one patient had a VHL (1.8%) mutation. Correlation between 18F-FDOPA metabolic parameters (tumor SUVmax, tumor SUVmean, tumor SUVmax/liver SUVmax, MTV 42%, total lesion uptake), urinary metanephrines (MNs), and plasma chromogranin A (CgA) were evaluated. RESULTS: All patients had positive 18F-FDOPA PET/CT. On univariate analysis, there was a strong correlation between all metabolic parameters and urinary MNs and plasma chromogranin A (CgA). The highest correlations were observed between total lesion (TL) uptake and the value of urinary MNs regardless of their nature (p = 8.10-15 and r = 0.80) and between MTV 42% and plasma CgA levels (p = 2.10-9, r = 0.74). On multivariate analysis, the correlation of uptake parameters and CgA levels did not persist further due to the relation of CgA and tumor diameter. A correlation between TL uptake and the normetanephrine/metanephrine ratio (NMN/MN) was also found, a finding that was in accordance with in vitro studies, which were found to have a higher catecholamine content in epinephrine producing PHEOs. CONCLUSION: This retrospective study shows a correlation between 18F-FDOPA uptake, especially using TL uptake, urinary MNs, and a PHEO biochemical phenotype. This illustrates that beyond its localization value, 18F-FDOPA PET further enables PHEO characterization at a specific metabolic level.
INTRODUCTION:18F-FDOPA illustrates the properties of uptake and storage of catecholamines in pheochromocytomas (PHEOs). Until now, the relationship between 18F-FDOPA quantitative parameters and a PHEO secretory profile has not been specifically evaluated. MATERIALS AND METHODS: Fifty-six patients (56% females, median age: 47.5 yrs) with non-metastatic PHEO, evaluated by 18F-FDOPA PET/CT, were included in this retrospective study. Forty-five patients had negative genetic testing (80.4%); five patients (8.9%) had RET, two patients (3.6%) had SDHB, two had SDHD (3.6%), one patient (1.8%) had NF1, and one patient had a VHL (1.8%) mutation. Correlation between 18F-FDOPA metabolic parameters (tumor SUVmax, tumor SUVmean, tumor SUVmax/liver SUVmax, MTV 42%, total lesion uptake), urinary metanephrines (MNs), and plasma chromogranin A (CgA) were evaluated. RESULTS: All patients had positive 18F-FDOPA PET/CT. On univariate analysis, there was a strong correlation between all metabolic parameters and urinary MNs and plasma chromogranin A (CgA). The highest correlations were observed between total lesion (TL) uptake and the value of urinary MNs regardless of their nature (p = 8.10-15 and r = 0.80) and between MTV 42% and plasma CgA levels (p = 2.10-9, r = 0.74). On multivariate analysis, the correlation of uptake parameters and CgA levels did not persist further due to the relation of CgA and tumor diameter. A correlation between TL uptake and the normetanephrine/metanephrine ratio (NMN/MN) was also found, a finding that was in accordance with in vitro studies, which were found to have a higher catecholamine content in epinephrine producing PHEOs. CONCLUSION: This retrospective study shows a correlation between 18F-FDOPA uptake, especially using TL uptake, urinary MNs, and a PHEO biochemical phenotype. This illustrates that beyond its localization value, 18F-FDOPA PET further enables PHEO characterization at a specific metabolic level.
Authors: Graeme Eisenhofer; Karel Pacak; Thanh-Truc Huynh; Nan Qin; Gennady Bratslavsky; W Marston Linehan; Massimo Mannelli; Peter Friberg; Stefan K Grebe; Henri J Timmers; Stefan R Bornstein; Jacques W M Lenders Journal: Endocr Relat Cancer Date: 2010-12-21 Impact factor: 5.678
Authors: Graeme Eisenhofer; Jacques W M Lenders; Henri Timmers; Massimo Mannelli; Stefan K Grebe; Lorenz C Hofbauer; Stefan R Bornstein; Oliver Tiebel; Karen Adams; Gennady Bratslavsky; W Marston Linehan; Karel Pacak Journal: Clin Chem Date: 2011-01-24 Impact factor: 8.327
Authors: Giorgio Treglia; Fabrizio Cocciolillo; Chiara de Waure; Francesco Di Nardo; Maria Rosaria Gualano; Paola Castaldi; Vittoria Rufini; Alessandro Giordano Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-23 Impact factor: 9.236
Authors: Graeme Eisenhofer; Thanh-Truc Huynh; Abdel Elkahloun; John C Morris; Gennady Bratslavsky; W Marston Linehan; Zhengping Zhuang; Brian M Balgley; Cheng S Lee; Massimo Mannelli; Jacques W M Lenders; Stefan R Bornstein; Karel Pacak Journal: Am J Physiol Endocrinol Metab Date: 2008-10-14 Impact factor: 4.310
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Bastiaan Havekes; Graeme Eisenhofer; Lucia Martiniova; Karen T Adams; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2009-10-28 Impact factor: 5.958
Authors: Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak Journal: Clin Endocrinol (Oxf) Date: 2009-06-08 Impact factor: 3.478
Authors: Helle-Brit Fiebrich; Johan R de Jong; Ido P Kema; Klaas Pieter Koopmans; Wim Sluiter; Rudi A J O Dierckx; Annemiek M Walenkamp; Thera P Links; Adrienne H Brouwers; Elisabeth G E de Vries Journal: Eur J Nucl Med Mol Imaging Date: 2011-06-23 Impact factor: 9.236
Authors: Benjamin Leroy-Freschini; Vincent Amodru; Pietro Addeo; Frédéric Sebag; Michel Vix; Laurent Brunaud; Marc Klein; Thibault Bahougne; Philippe Bachellier; Frédéric Castinetti; Bernard Goichot; Elodie Chevalier; David Taieb; Alessio Imperiale Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-07 Impact factor: 9.236
Authors: Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: J Nucl Med Date: 2019-04-06 Impact factor: 10.057
Authors: Walter Noordzij; Andor W J M Glaudemans; Mirte Schaafsma; Anouk N A van der Horst-Schrivers; Riemer H J A Slart; André P van Beek; Michiel N Kerstens Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-22 Impact factor: 9.236
Authors: Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Alexander Ling; Frank I Lin; Daniel A Pryma; Karel Pacak Journal: J Nucl Med Date: 2021-08-01 Impact factor: 10.057
Authors: Domenico Albano; Francesco Agnello; Federico Midiri; Giusy Pecoraro; Alberto Bruno; Pierpaolo Alongi; Patrizia Toia; Giuseppe Di Buono; Antonino Agrusa; Luca Maria Sconfienza; Salvatore Pardo; Ludovico La Grutta; Massimo Midiri; Massimo Galia Journal: Insights Imaging Date: 2019-01-25